source
- FDA drug division chief Tracy Beth Høeg expected to depart amid leadership shakeupTracy Beth Høeg, who leads the FDA’s Center for Drug Evaluation and Research, is reported to be leaving the agency. Her exit comes shortly after former Commissioner Marty Makary stepped down, sugg…
- Candel Therapeutics shares 20-month follow-up data for its prostate cancer candidate ahead of FDA filingCandel Therapeutics announced that it has completed a long-term follow‑up study of patients treated with its prostate cancer drug. The data extend to about 20 months after treatment and are intende…